What is the 13F Pro Quality Score for LXRX?

13F Pro ranks LEXICON PHARMACEUTICALS, INC. (LXRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LXRX's current score at https://13fpro.ai/company/LXRX (free sign-up required for the full ranking).

Which hedge funds own the most LXRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LXRX include Artal Group S.A., FMR, Siren, L.L.C.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/LXRX as soon as new 13F filings post.

Where does 13F Pro source LXRX data?

All LEXICON PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. LEXICON PHARMACEUTICALS, INC. files with the SEC under CIK 1062822. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LXRX in?

LEXICON PHARMACEUTICALS, INC. (LXRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LXRX research updated on 13F Pro?

LXRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LEXICON PHARMACEUTICALS, INC.(LXRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1062822 LXRX stock profile & AI dashboard →

13F Pro Quality Score

33.7/100

Rank #2,382 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

6.5/100

Balance Sheet

9.0/100

Earnings Quality

8.5/100

Free Cash Flow

5.3/100

Institutional Flow

81.4/100

Revenue Scale

7.4/100

Dilution Risk

7.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LXRX Scores 34/100

exact factor attribution · 2026-09-11

LXRX's composite is driven by revenue growth and earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Earnings growth

+2.3 pts

95th pct

Institutional flow

+1.6 pts

81th pct

Shareholder dilution

-2.1 pts

7th pct

Capital efficiency

-4.1 pts

9th pct

Earnings quality

-4.2 pts

9th pct

Scale

-6.4 pts

7th pct

Profitability

-6.5 pts

7th pct

Free cash flow

-6.7 pts

5th pct

Latest change (2026-08-06): 33 → 27 · ↓ Revenue scale 14→2; ↓ Profit margin 11→2

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LXRX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for LEXICON PHARMACEUTICALS, INC. (LXRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LXRX at 33.7/100 on a 32-signal composite quality model, placing it at rank #2,382 of 2,961 stocks — the bottom half of the AI-ranked universe. LXRX scores in the top quartile across revenue growth (99.3), institutional flow (81.4). Areas of concern include free cash flow (5.3) and profitability (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LEXICON PHARMACEUTICALS, INC. reports quarterly revenue of $692.0K, net income of $-31.8M. Top institutional holders of LXRX by reported 13-F value include Artal Group S.A., FMR, Siren, L.L.C., based on the most recent SEC filings. LXRX trades on the Nasdaq exchange and files with the SEC under CIK 1062822. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEXICON PHARMACEUTICALS, INC. directly from SEC EDGAR. LEXICON PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 6 and 40 since 2021, currently 33.7 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about LEXICON PHARMACEUTICALS, INC.

Quirks, history, and lore behind LXRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
Annual revenue in the low hundreds of millions, driven almost entirely by one approved drug — a tough way to run a business, but not unusual in specialty pharma.
3
The History
Founded in the late 1990s, it spent decades building a proprietary gene knockout mouse platform to systematically identify drug targets — a genuinely unusual research strategy for a small biotech.
4
The Secret
Its signature technology, the OmniBank knockout mouse library, let scientists knock out virtually every gene in the mouse genome to figure out what each one actually does in disease.
5
The Lore
After years of pipeline heartbreak, the company finally landed an approved drug for a rare heart condition — ATTR cardiomyopathy — putting it in competition with much larger players in a suddenly hot disease area.
6
The Giveaway
Its approved drug sotagliflozin (also used in heart failure) and its ticker LXRX are the breadcrumbs — a Woodlands, Texas biotech that bet its whole existence on mouse genetics paying off.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$692.0K

Net Income

Q2 2026

$-31.8M

ROIC

Q2 2026

-47.0%

D/E Ratio

Q2 2026

0.29

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+60.2% YoY

$49.8MFY 2025

FY22 $139.0KFY23 $1.2MFY24 $31.1MFY25 $49.8M

Net Income

+74.9% YoY

$-50.3MFY 2025

FY22 $-101.9MFY23 $-177.1MFY24 $-200.4MFY25 $-50.3M

Operating Income

+75.2% YoY

$-48.9MFY 2025

FY22 $-100.8MFY23 $-171.8MFY24 $-197.1MFY25 $-48.9M

EPS (Diluted)

+77.8% YoY

$-0.14FY 2025

FY22 $-0.62FY23 $-0.80FY24 $-0.63FY25 $-0.14

Total Assets

-38.0% YoY

$185.0MFY 2025

FY22 $194.3MFY23 $229.4MFY24 $298.4MFY25 $185.0M

Total Debt

-46.2% YoY

$54.0MFY 2025

FY22 $48.6MFY23 $99.5MFY24 $100.3MFY25 $54.0M

Op. Cash Flow

+62.0% YoY

$-67.9MFY 2025

FY22 $-88.9MFY23 $-161.9MFY24 $-178.8MFY25 $-67.9M

Free Cash Flow

+62.3% YoY

$-67.9MFY 2025

FY22 $-90.2MFY23 $-162.4MFY24 $-179.8MFY25 $-67.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$49.8M +60.2%	$31.1M +2481.5%	$1.2M +766.2%	$139.0K -53.4%	$298.0K -98.8%	$24.0M
Net Income	$-50.3M +74.9%	$-200.4M -13.1%	$-177.1M -73.7%	$-101.9M -16.2%	$-87.8M -49.8%	$-58.6M
Operating Income	$-48.9M +75.2%	$-197.1M -14.8%	$-171.8M -70.5%	$-100.8M -15.7%	$-87.1M -82.2%	$-47.8M
EPS (Diluted)	$-0.14 +77.8%	$-0.63 +21.3%	$-0.80 -29.0%	$-0.62 -3.3%	$-0.60 -13.2%	$-0.53
Total Assets	$185.0M -38.0%	$298.4M +30.1%	$229.4M +18.1%	$194.3M +41.9%	$136.9M -32.8%	$203.8M
Total Debt	$54.0M -46.2%	$100.3M +0.8%	$99.5M +104.7%	$48.6M +3950.0%	$1.2M -90.2%	$12.3M
Operating Cash Flow	$-67.9M +62.0%	$-178.8M -10.4%	$-161.9M -82.2%	$-88.9M -2.1%	$-87.0M +39.1%	$-143.0M
Free Cash Flow	$-67.9M +62.3%	$-179.8M -10.7%	$-162.4M -80.1%	$-90.2M -2.2%	$-88.2M +38.3%	$-143.1M

Get alerted when LXRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LEXICON PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LXRX

Artal Group S.A.
$420.4M175,156,062 sh
FMR LLC
$124.3M51,782,045 sh
Siren, L.L.C.
$106.3M44,303,518 sh
Sessa Capital IM, L.P.
$45.5M18,960,836 sh
BlackRock, Inc.
$41.6M17,348,741 sh
VANGUARD CAPITAL MANAGEMENT LLC
$23.8M9,901,208 sh
Point72 Asset Management, L.P.
$19.8M8,251,325 sh
GEODE CAPITAL MANAGEMENT, LLC
$15.0M6,244,372 sh
STATE STREET CORP
$11.8M4,917,769 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.7M2,357,749 sh

Fund	Value	Shares
Artal Group S.A.	$420.4M	175,156,062
FMR LLC	$124.3M	51,782,045
Siren, L.L.C.	$106.3M	44,303,518
Sessa Capital IM, L.P.	$45.5M	18,960,836
BlackRock, Inc.	$41.6M	17,348,741
VANGUARD CAPITAL MANAGEMENT LLC	$23.8M	9,901,208
Point72 Asset Management, L.P.	$19.8M	8,251,325
GEODE CAPITAL MANAGEMENT, LLC	$15.0M	6,244,372
STATE STREET CORP	$11.8M	4,917,769
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.7M	2,357,749

Companies Similar to LXRX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IVVD

Invivyd, Inc.

AI score

Similar quality profile · 5 shared holders

Siren, L.L.C.ADAR1 Capital Management, LLC Ikarian Capital, LLC

PGEN

PRECIGEN, INC.

AI score

Similar quality profile · 6 shared holders

Virtus Investment Advisers, LLC AXQ CAPITAL, LP Fortis Group Advisors, LLC

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 3 shared holders

Ishara Investments LP ADAR1 Capital Management, LLC Virtus Investment Advisers, LLC

OBIO

Orchestra BioMed Holdings, Inc.

AI score

Similar quality profile · 2 shared holders

AXQ CAPITAL, LP Point72 Asia (Singapore) Pte. Ltd.

CUE

Cue Biopharma, Inc.

AI score

Similar quality profile · 2 shared holders

ADAR1 Capital Management, LLC Ikarian Capital, LLC

CYTK

CYTOKINETICS INC

AI score

Similar quality profile · 4 shared holders

Siren, L.L.C.Ishara Investments LP ADAR1 Capital Management, LLC

TNXP

Tonix Pharmaceuticals Holding Corp.

AI score

Similar quality profile · 1 shared holders

Ishara Investments LP

PROK

PROKIDNEY CORP.

AI score

Similar quality profile · 3 shared holders

Virtus Investment Advisers, LLC AXQ CAPITAL, LP R Squared Ltd

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LXRX on your watchlist

Track score changes the day LEXICON PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LXRX a good stock to buy?

13F Pro's AI-powered analysis of LEXICON PHARMACEUTICALS, INC. (LXRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LXRX are available on the LXRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LXRX is classified as a small company.

Which hedge funds own LXRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LXRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LEXICON PHARMACEUTICALS, INC.'s investment landscape.